Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CNSX:CHVNASDAQ:CURNYSEARCA:CURECNSX:VP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCHVCanada House Wellness Group$0.00$0.00▼$0.00N/AN/AN/A156,525 shsCURNeuralstem$0.70-1.9%$1.06$1.10▼$13.78$1.47M1.81236,278 shs117,525 shsCUREDirexion Daily Healthcare Bull 3x Shares$77.41-0.7%$78.56$67.16▼$143.51$135.47M1.9367,856 shs46,168 shsVPVodis Pharmaceuticals$0.00$0.16▼$0.62N/AN/A1,714 shs51,582 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCHVCanada House Wellness Group0.00%0.00%0.00%0.00%0.00%CURNeuralstem-1.64%+11.44%-11.85%+3.64%-84.41%CUREDirexion Daily Healthcare Bull 3x Shares-0.69%+4.09%+5.84%-25.09%-34.46%VPVodis Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCHVCanada House Wellness GroupN/AN/AN/AN/AN/AN/AN/AN/ACURNeuralstemN/AN/AN/AN/AN/AN/AN/AN/ACUREDirexion Daily Healthcare Bull 3x SharesN/AN/AN/AN/AN/AN/AN/AN/AVPVodis PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCHVCanada House Wellness Group 0.00N/AN/AN/ACURNeuralstem 0.00N/AN/AN/ACUREDirexion Daily Healthcare Bull 3x Shares 2.69Moderate Buy$77.41N/AVPVodis Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCHVCanada House Wellness GroupN/AN/AN/AN/AN/AN/ACURNeuralstem$260K5.65N/AN/A$6.64 per share0.11CUREDirexion Daily Healthcare Bull 3x SharesN/AN/AN/AN/AN/AN/AVPVodis PharmaceuticalsN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCHVCanada House Wellness GroupN/AN/A0.00N/AN/AN/AN/AN/AN/ACURNeuralstem-$4.93MN/A0.00∞N/A-39,417.64%-170.51%-110.16%N/ACUREDirexion Daily Healthcare Bull 3x SharesN/AN/A20.81∞N/AN/AN/AN/AN/AVPVodis PharmaceuticalsN/AN/A0.00N/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCHVCanada House Wellness GroupN/AN/AN/AN/AN/ACURNeuralstemN/AN/AN/AN/AN/ACUREDirexion Daily Healthcare Bull 3x Shares$1.101.42%N/AN/AN/AVPVodis PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCHVCanada House Wellness GroupN/AN/AN/ACURNeuralstemN/A2.532.53CUREDirexion Daily Healthcare Bull 3x SharesN/AN/AN/AVPVodis PharmaceuticalsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCHVCanada House Wellness GroupN/ACURNeuralstem38.30%CUREDirexion Daily Healthcare Bull 3x SharesN/AVPVodis PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipCHVCanada House Wellness GroupN/ACURNeuralstem5.38%CUREDirexion Daily Healthcare Bull 3x SharesN/AVPVodis PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCHVCanada House Wellness Group43,800N/AN/ANot OptionableCURNeuralstem62.10 millionN/ANot OptionableCUREDirexion Daily Healthcare Bull 3x SharesN/A1.75 millionN/ANot OptionableVPVodis PharmaceuticalsN/AN/AN/ANot OptionableVP, CUR, CHV, and CURE HeadlinesRecent News About These CompaniesVP debate 'spin room' scene: Talking points and unscripted momentsOctober 22, 2024 | usatoday.comPharma execs donated more to Democrats in campaign’s final stretchOctober 21, 2024 | statnews.comSVitalPath hires Nicole Ramus as global sales VPOctober 18, 2024 | medicaldesignandoutsourcing.comMVice President Harris in ‘Excellent Health,’ Medical Report StatesOctober 14, 2024 | msn.comVance Confident, Walz Uneven in VP Debate Heavy on PolicyOctober 2, 2024 | wsj.comRead the full VP debate transcript from the Walz-Vance showdownOctober 2, 2024 | cbsnews.comAs Investigations Swirl, Another Adams Official ResignsSeptember 24, 2024 | nytimes.comTHE CONTRERAS REPORT: Governor Newsom, veto Big Pharma’s grab for more profitsSeptember 24, 2024 | ivpressonline.comITris Pharma Promotes Naidu to Chief Commercial OfficerSeptember 21, 2024 | njbmagazine.comNNo one used to care about the vice presidency. Here's how (and why) that's changed.September 15, 2024 | pbs.orgPTonix Pharmaceuticals Announces Appointment of Thomas Englese as Executive Vice President of Commercial OperationsSeptember 10, 2024 | markets.businessinsider.comKalVista Pharma Appoints Brian Piekos As New CFOSeptember 10, 2024 | markets.businessinsider.comFor pharma, Trump versus Harris is a showdown between two industry foesAugust 27, 2024 | politifact.comPAvive names Katerina Miras as VP of marketingAugust 21, 2024 | massdevice.comThis Bipartisan Bill Would Upend America's Pharmaceutical IndustryAugust 20, 2024 | forbes.comHow they are reporting it: Kamala Harris' VP pick, Tim WalzAugust 9, 2024 | reuters.comKamala Harris campaign expected to announce VP running mate Tuesday morningAugust 7, 2024 | cbsnews.comVP Pick Walz’s Healthcare Policies Align With Harris’s RecordAugust 7, 2024 | forbes.comWhere VP picks stand on pharmaceutical costsAugust 6, 2024 | beckershospitalreview.comBWhere Harris' VP Options Stand on HealthcareAugust 2, 2024 | msn.comMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Companies to Buy on This Early Cycle RecoveryBy Gabriel Osorio-Mazilli | June 3, 2025View 3 Companies to Buy on This Early Cycle RecoveryApplied Digital: Now the High-Stakes Race to Build BeginsBy Jeffrey Neal Johnson | June 17, 2025View Applied Digital: Now the High-Stakes Race to Build BeginsNew Catalysts to Drive NVIDIA’s Stock Price Even HigherBy Thomas Hughes | June 16, 2025View New Catalysts to Drive NVIDIA’s Stock Price Even HigherIn a Historic Shift, 2 Cybersecurity Stocks Plan to Buyback StockBy Leo Miller | June 9, 2025View In a Historic Shift, 2 Cybersecurity Stocks Plan to Buyback StockTop 3 Bank Stocks to Watch as Fed Rate Cuts LoomBy Chris Markoch | June 25, 2025View Top 3 Bank Stocks to Watch as Fed Rate Cuts LoomVP, CUR, CHV, and CURE Company DescriptionsCanada House Wellness Group CNSX:CHVCanada House Cannabis Group Inc., through its subsidiaries, provides medical grade cannabis products in Canada. The company offers cannabinoid therapy products and services to patients, as well as owns and operates medicinal cannabis clinics. It also provides a cloud-based software that links physicians, providers, and patients to data that supports treatment with medical cannabis. The company serves its products under the Abba Medix, ICM Air, ICM Fogo, H-Series, Fleurs de chez nous, and Vandoos brand names. Canada House Cannabis Group Inc. is headquartered in Pickering, Canada.Neuralstem NASDAQ:CURNeuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidate is NSI-189, a chemical entity, which has been completed Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical study for the treatment-refractory depression, Angelman Syndrome, Alzheimer's disease, ischemic stroke, diabetic neuropathy, irradiation-induced cognitive deficit, and long-term potentiation enhancement. The company also develops NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease; Phase II clinical trial for the treatment of chronic ischemic stroke; and Phase I clinical trials for the treatment of chronic spinal cord injury, as well as is in preclinical study for the traumatic brain injury. In addition, it develops NSI-532, which is in preclinical study for treatment of Alzheimer's disease; and NSI-777 that is in preclinical study for treatment of human demyelinating diseases. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.Direxion Daily Healthcare Bull 3x Shares NYSEARCA:CURE$77.41 -0.54 (-0.69%) As of 06/27/2025 04:10 PM EasternThe Direxion Daily Healthcare Bull 3X Shares (CURE) is an exchange-traded fund that is based on the Health Care Select Sector index. The fund provides 3x levered exposure to a market cap weighted sub-index of the S&P 500 that tracks the performance of US listed health care companies. CURE was launched on Jun 15, 2011 and is managed by Direxion.Vodis Pharmaceuticals CNSX:VPVodis Pharmaceuticals Inc. operates as an application stage company for producing medical marijuana. It operates in Canada and the United States. The company is based in Delta, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Addition by Subtraction: Intel’s New Strategy Energizes Investors NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Broadcom’s Big VMware Update: A Threat to Public Cloud Giants? Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
